The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
**Background:** Few studies have attempted to assess the effectiveness of formulary management in reducing the antipsychotic costs and utilization across U.S. state Medicaid programs, despite concerns about the potential impact of such formulary management on Medicaid patient health outcomes. **Obj...
Saved in:
Main Authors: | Christian Frois, Thomas O’Connell, Jacqueline Pesa, John Fastenau |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2013-05-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9853 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Follow-up Care among Medicaid Patients with Schizophrenia treated with Antipsychotics in the Inpatient Setting
by: Amanda M. Farr, et al.
Published: (2014-10-01) -
Medicaid Eligibility and Time to Re-incarceration Among Previously Incarcerated Subjects With Schizophrenia
by: Chris Kozma, et al.
Published: (2016-10-01) -
Association between a publicly funded universal drug program and antipsychotic and antidepressant medication dispensing to children
by: Sophie A. Kitchen, et al.
Published: (2025-02-01) -
Burden of Comorbidities and Healthcare Resource Utilization Among Medicaid-Enrolled Extremely Premature Infants
by: Meredith E. Mowitz, et al.
Published: (2022-12-01) -
Regarding "Burden of Comorbidities and Healthcare Resource Utilization Among Medicaid-Enrolled Extremely Premature Infants"
by: Ava Tsapatsaris, et al.
Published: (2023-04-01)